27
Participants
Start Date
December 13, 2021
Primary Completion Date
August 13, 2022
Study Completion Date
September 1, 2022
Semaglutide 1.34 mg/mL
Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
Semaglutide 3.0 mg/mL
Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum. once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
NNC0480-0389 10 mg/mL
NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
NNC0480-0389 30 mg/mL
NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
Microgynon®
Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
Novo Nordisk Investigational Site, Berlin
Lead Sponsor
Novo Nordisk A/S
INDUSTRY